Co-Diagnostics abandons annual meeting after 4 failed quorum attempts; plans special meeting

Co-Diagnostics, Inc.

Annual Meeting held September 3, 2026 lacked a quorum; reconvened September 24, September 30 and October 14, 2026 with no quorum on any date.
Company determined not to adjourn again; no business was transacted and none of the meeting's proposals were voted on.
Co-Diagnostics intends to seek stockholder approval of those proposals at a special meeting on a future, still-unannounced date.
Date, time and location of any special meeting will be disclosed in proxy materials filed with the SEC and sent to stockholders.
Signed by CEO Dwight Egan on October 15, 2026; common stock (CODX) trades on the Nasdaq Capital Market.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.